Katherine Y. Look - Concepedia

Author

Katherine Y. Look

Indiana University – Purdue University Indianapolis

Also Known As

K LOOK, K Look, K Y Look, K. Look, K. Y. LOOK, K. Y. Look, K.Y. LOOK, K.Y. Look, Katherine Look, Katherine Y Look

113

Publications

7.5K

Citations

H-Index

Concepts

All Affiliations

Indiana University – Purdue University Indianapolis Indiana University School of Medicine Gynecologic Oncology Group Roswell Park Comprehensive Cancer Center University Medical Center

About

Katherine Y. Look is an author at Indiana University – Purdue University Indianapolis specializing in medicine, obstetrics, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	44	2.8K
2	Public Health	3	3	166
3	Health Sciences	2	2	668
4	Arts	1	1	48
5	Natural Sciences	1	1	64

Katherine Y. Look

Publications

7.2K

Citations

H-Index

Page 1

	Year	Citations
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer William P. McGuire, William J. Hoskins, Mark F. Brady, New England Journal of Medicine	1996	2.9K
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240) Krishnansu S. Tewari, Michael W. Sill, Richard T. Penson, The Lancet Advanced Cervical CancerCervical Cancer ManagementCervical CancerCervical HealthMedicine	2017	656
Phase III Trial of Doxorubicin Plus Cisplatin With or Without Paclitaxel Plus Filgrastim in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study Gini F. Fleming, Virginia L. Brunetto, David Cella, Journal of Clinical Oncology	2004	561
Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study Jeffrey G. Bell, Mark F. Brady, Robert C. Young, Gynecologic Oncology Adjuvant CarboplatinVersus SixMedicinePhase Iii TrialGynecology	2006	305
Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers Paul J. Goodfellow, Barbara M. Buttin, Thomas J. Herzog, Proceedings of the National Academy of Sciences Epigenetic ChangeGeneticsGynecologyPathologyUnselected Series	2003	237
Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study Katherine Y. Look, Alan Sandler, John A. Blessing, Gynecologic Oncology Phase Ii TrialMedicineMetronomic TherapyUterine LeiomyosarcomaGynecology	2004	163
Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). William P. McGuire, W.J. Hoskins, M F Brady, PubMed	1996	152
An Analysis of Cell Type in Patients with Surgically Staged Stage IB Carcinoma of the Cervix: A Gynecologic Oncology Group Study Katherine Y. Look, Virginia L. Brunetto, Daniel L. Clarke‐Pearson, Gynecologic Oncology	1996	151
The Fate of the Ovaries after Radical Hysterectomy and Ovarian Transposition Daniel D. Feeney, David H. Moore, Katherine Y. Look, Gynecologic Oncology Gynecologic SurgeryGynecological SurgeryFertilityOvarian TranspositionReproductive Health	1995	128
A Prospective Controlled Trial of Early Postoperative Oral Intake Following Major Abdominal Gynecologic Surgery Jeanne M. Schilder, Jean Hurteau, Katherine Y. Look, Gynecologic Oncology Gynecologic SurgeryProspective Controlled TrialGynecologyOutcomes ResearchPost-operative Care	1997	127

Page 1